Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0IK5F
|
|||
Former ID |
DCL000500
|
|||
Drug Name |
BSI-201
|
|||
Synonyms |
Iniparib; NIBA; INO2BA; IND-71677; SAR-240550; Iniparib, NSC-746045, IND-71677, BSI201, BSI-201; 4-Iodo-3-nitrobenzamide; 4-iodo-3-nitro-benzamide
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 3 | [1], [2] | |
Company |
Sanofi-Aventis
|
|||
Structure |
Download2D MOL |
|||
Formula |
C7H5IN2O3
|
|||
Canonical SMILES |
C1=CC(=C(C=C1C(=O)N)[N+](=O)[O-])I
|
|||
InChI |
1S/C7H5IN2O3/c8-5-2-1-4(7(9)11)3-6(5)10(12)13/h1-3H,(H2,9,11)
|
|||
InChIKey |
MDOJTZQKHMAPBK-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 160003-66-7
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
14751362, 24106025, 44832080, 57373346, 74888203, 93581007, 99431610, 99436974, 103769589, 117670493, 123392548, 124756988, 125000894, 125163793, 125569557, 126574583, 126671638, 126724678, 128580330, 131480675, 134964401, 135264510, 135594245, 135626650, 135653765, 136340146, 136367287, 136368021, 136372114, 137125740, 137275940, 141658863, 143498513, 144115758, 151993182, 152239759, 152258338, 152344509, 160647176, 160818575, 162011826, 162034147, 162145211, 162165597, 162189524, 162798607, 164046169, 164194026, 164761194, 165238048
|
|||
ChEBI ID |
CHEBI:95067
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Poly [ADP-ribose] polymerase (PARP) | Target Info | Modulator | [2] |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8360). | |||
REF 2 | Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012 Mar 15;18(6):1655-62. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.